Morepen Labs launches diabetes drug Empamore

Morepen manufactures Empagliflozin (API) in its US FDA-approved facilities and already has European DMF Morepen Laboratories has launched Empamore, a game-changing treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF)and Chronic Kidney Disease (CKD). Morepen manufactures Empagliflozin (API) in its US FDA-approved facilities and already has European D